Monitor ABC Court proceedings for approval and any competing bids. The stalking horse protections include a 4% breakup fee (~$159K) and expense reimbursement up to $300K. If approved, the deal could transform cbdMD's revenue profile and reduce hemp concentration, but the 19.9% stock issuance and preferred conversion price reduction are dilutive to existing shareholders.
Price Chart
Executive Summary
cbdMD entered a definitive asset purchase agreement to acquire Twinlab's operating assets (including Twinlab, Reserveage, Metabolife, and Alvita Tea brands) through an assignment for the benefit of creditors (ABC) proceeding. The total consideration is $3,979,805, consisting of assumption of ~$1.75M in secured debt, issuance of 2,229,805 shares (19.9% of outstanding common stock), and assumption of certain liabilities. The company also reduced the Series B Convertible Preferred Stock conversion price from $1.00 to $0.60 per share, increasing potential dilution. The acquisition is subject to ABC Court approval and is expected to close in cbdMD's first fiscal quarter.
Key Financial Metrics
Key Facts
- cbdMD entered into an Asset Purchase Agreement to acquire Twinlab brands through an ABC proceeding
- Aggregate consideration: $3,979,805, including $1.75M debt assumption and 2,229,805 shares (19.9% of outstanding common stock)
- Combined trailing twelve-month revenue ending June 2026 approximately $30 million, representing ~40% increase over cbdMD's standalone revenue
- Transaction subject to ABC Court approval and customary closing conditions; expected to close in first fiscal quarter
- Series B Convertible Preferred Stock conversion price reduced from $1.00 to $0.60 per share, effective September 2, 2026 (591,207 shares outstanding)
Financial Impact
Acquisition expected to increase revenues by ~40% to ~$30M, but involves significant dilution (19.9% of common stock) and assumption of $1.75M secured debt. Series B conversion price reduction adds further potential dilution.
Risk Factors
- ABC Court may not approve the sale or may require an auction, potentially leading to a competing bid
- Twinlab is delinquent in SEC reports, adding regulatory and integration uncertainty
- Significant dilution from 19.9% common stock issuance and Series B conversion price reduction
- Integration risks and potential disruption to Twinlab's retail and wholesale relationships
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-029455 |
| Exhibit: ex_1011653.htm | 0001437749-26-029455 |
| Exhibit: ex_1011652.htm | 0001437749-26-029455 |
| Document: ycbd20260901_8k.htm | 0001437749-26-029455 |
| Document: 0001437749-26-029455-index-headers.html | 0001437749-26-029455 |
| Document: 0001437749-26-029455-index.html | 0001437749-26-029455 |
| Document: 0001437749-26-029455.txt | 0001437749-26-029455 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | Press Release | $0.5000 $0.4530 | ▼ −9.40% | ▼ −9.32% | $0.3700 (−26.00%) |
Sep 2, 2026 7w ago | 8-K | $0.5000 $0.4530 | ▼ −9.40% | ▼ −9.32% | $0.3700 (−26.00%) |
Aug 10, 2026 11w ago | Press Release | $0.5660 $0.4997 | ▼ −11.71% | ▼ −10.80% | $0.3700 (−34.63%) |
May 20, 2026 22w ago | 8-K | $0.7790 $0.6901 | ▼ −11.41% | ▼ −11.75% | $0.3700 (−52.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers